🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

Are Psychedelics the Next Pot Stocks?

Published 2020-12-04, 08:00 a/m
Are Psychedelics the Next Pot Stocks?

Over the last decade, the pot stock wave was one of the best opportunities for investors to make money. However, by the time they became well known for most investors, almost all the money had already been made.

A few years down the road now, some stocks saw incredible growth, and the entire sector boomed for years. While most have come back down from their all-time highs, the sector is still valued considerably high. So, for long-term investors who held the whole time, you’ve made a considerable amount of money.

An opportunity like pot stocks doesn’t come around very often. It’s not like a pharmaceutical drug being approved or a new technology being made. Cannabis is something that can’t be patented and has been around and used for a long time. It’s a commodity that’s been illegal until recently.

Now that cannabis has been legalized for a few years, much of the rapid growth potential is behind us. However, it looks like the next big opportunity could be in the legalization of psychedelics.

The science of psychedelics For years, it’s been hypothesized by many scientists that psychedelics could offer some benefits much like cannabis. In the past, research has been done by Johns Hopkins University, one of the most famous medical research universities in the United States, to show the positive effects the psychedelics could have.

Today, Johns Hopkins is running a new study that seems the benefits could be even greater than what was once expected.

It’s still early in the study, but it looks like psilocybin, the active drug in what’s commonly referred to as magic mushrooms, could have numerous positive effects on severe mental health conditions such as anxiety, depression, and post-traumatic stress disorder.

Furthermore, in the most recent U.S. election, Oregon voted to allow the study of magic mushrooms, and the District of Columbia voted to decriminalize the drug.

This is a major positive and the first step on the road to mass acceptance and adoption. Since the election, the stock is up over 65%, showing how important a development it was.

Big-name investors Another reason that makes the psychedelic space so intriguing is the big-name investors behind these startups.

The first big-name investor showing the psychedelics could have a tonne of potential is Bruce Linton. Bruce is best known for being the CEO of Canopy Growth (TSX:WEED)(NYSE:CGC). He was a pioneer in the pot sector, the co-founder and CEO of the first cannabis stock to be publicly traded. His vision is what made Canopy the most dominant player in the industry, so the fact that he is behind this company says a lot.

Another popular investor is Kevin O’Leary. Kevin is best known for his many appearances on TV, and if you’ve ever heard Kevin speak, he is more of a conservative investor. So, the fact the Kevin O’Leary sees an opportunity and has gotten behind psychedelic medicine says a lot.

Both these big-name investors are shareholders in Mind Medicine (Mind Med) (OTC:MMED). So, if you’re looking for a stock to invest in, this looks to be your top choice.

Pot stocks vs. psychedelics Pot stocks like Canopy Growth still offer investors significant potential over the long term, but the days of massive short-term growth are over.

That can’t be said for psychedelic stocks, which haven’t even crossed the radar of several investors. While this could be an opportunity, it may still be early in the process. Plus, there is no telling how long until psychedelic medicine becomes mainstream. So, if you decide to buy a psychedelic stock today like Mind Med, it should be viewed as a long-term investment.

However, while you may have to hold the stock for five or 10 years to see some major growth, if it grows to the same degree as pot stocks when they finally skyrocketed, it will be well worth the wait.

The post Are Psychedelics the Next Pot Stocks? appeared first on The Motley Fool Canada.

Fool contributor Daniel Da Costa has no position in any of the stocks mentioned.

The Motley Fool’s purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool Canada’s free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. Motley Fool Canada 2020

This Article Was First Published on The Motley Fool

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.